-
Efavirenz
- Teratogenic
- Neuropsychiatric
- Hyperlipidemia
-
Nevaripine
- Hepatotoxic
- Women with CD4 >250
- Men with CD4 > 400
- Hyperlipidemia
-
Etraverine
Well tolerated
-
Atazanavir
- Hyperbilirubinemia
- PR interval prolongation
- Low nephrolithiasis
-
-
-
-
Indinavir
- Nephrolithiasis
- GI intolerance
-
Lopinavir/ritonavir
GI intolerance
-
-
Saquinavir
GI intolerance
-
-
Abacavir
- Hypersensitivity reaction (once)
- Rash
- CV effects
-
Didanosine
- GI intolerance
- Pancreatitis
- Peripheral neuropathy
-
Stavudine
- Peripheral neuropathy
- Pancreatitis
- More lactic acidosis/hepatic steatosis and lipodystrophy
- Hyperlipidemia
-
Tenofovir
- Headache
- GI intolerance
- Renal impairment
-
Zidovudine
- Headache
- GI intolerance
- Bone marrow suppression
-
Emtricitabine
Hyperpigmentation
-
NNRTI
- Rash (especially nevirapine)
- DDI (inducers of CYP3A4)
-
PI
- Hyperlipidemia (not Atazanavir)
- Insulin resistance and diabetes (not Atazanavir)
- Lipodystrophy; lipoatrophy (not Atazanavir)
- Elevated liver function tests
- Increased bleeding risk in hemophiliacs
- DDI (inhibit CYP3A4)
- Osteonecrosis
-
NNRTI
- Lactic acidosis and hepatic steatosis (higher incidence with stavudine)
- Lipodystrophy (higher incidence with stavudine)
-
Enfuvirtide
- Injection-site reactions
- Hypersensitivity
- Increased risk of bacterial pneumonia
-
Maraviroc
- Abdominal pain
- URTI
- Cough
- Hepatotoxic
- Musculoskeletal symptoms
- Rash
- Orthostatic hypotension
-
Raltegravir
- Nausea
- Headache
- Diarrhea
- CPK elevation
|
|
